Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GALCANEZUMAB-GNLM Cause Extra dose administered? 39 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 39 reports of Extra dose administered have been filed in association with GALCANEZUMAB-GNLM. This represents 0.2% of all adverse event reports for GALCANEZUMAB-GNLM.

39
Reports of Extra dose administered with GALCANEZUMAB-GNLM
0.2%
of all GALCANEZUMAB-GNLM reports
0
Deaths
1
Hospitalizations

How Dangerous Is Extra dose administered From GALCANEZUMAB-GNLM?

Of the 39 reports, 1 (2.6%) required hospitalization.

Is Extra dose administered Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GALCANEZUMAB-GNLM. However, 39 reports have been filed with the FAERS database.

What Other Side Effects Does GALCANEZUMAB-GNLM Cause?

Injection site pain (6,622) Underdose (2,909) Migraine (2,612) Headache (2,104) Drug ineffective (1,610) Product dose omission issue (1,591) Injection site haemorrhage (1,415) Accidental underdose (1,064) Injection site erythema (1,052) Injection site pruritus (774)

What Other Drugs Cause Extra dose administered?

TIRZEPATIDE (6,774) DULAGLUTIDE (3,047) LORATADINE (1,556) DUPILUMAB (1,422) FEXOFENADINE (1,413) NAPROXEN (908) POLYETHYLENE GLYCOL 3350 (589) ACETAMINOPHEN (552) DALFAMPRIDINE (519) FLUTICASONE\SALMETEROL (499)

Which GALCANEZUMAB-GNLM Alternatives Have Lower Extra dose administered Risk?

GALCANEZUMAB-GNLM vs GALLIUM GA-OZETOTIDE GALCANEZUMAB-GNLM vs GALSULFASE GALCANEZUMAB-GNLM vs GAMMAGARD LIQUID GALCANEZUMAB-GNLM vs GANAXOLONE GALCANEZUMAB-GNLM vs GANCICLOVIR

Related Pages

GALCANEZUMAB-GNLM Full Profile All Extra dose administered Reports All Drugs Causing Extra dose administered GALCANEZUMAB-GNLM Demographics